Savvy Stock Picks

Trimble Navigation Limited (Public, NASDAQ:TRMB) decreased -0.70%, to close at $39.93 and its overall traded volume was 322,176.00 shares during the last session against its average volume of 493,006.00. TRMB opened the day at $40.10, it made an intraday low of $39.93 and an intraday high of $40.57. The stock has a 52 week low of $22.85 and 52 week high of $42.19. TRMB’s market capitalization is 4.80B and it has 120.09M outstanding shares.

About Trimble Navigation Limited (Public, NASDAQ:TRMB)

Trimble Navigation Limited (Trimble) provides advanced positioning product solutions, to commercial and government users. The principle applications served include surveying, agriculture, construction, asset management, mapping and mobile resource management. Products include agricultural and construction equipment, guidance systems, surveying instruments, systems that track fleets of vehicles and data collection systems that enable the management of large amounts of geo-referenced information. In addition, Trimble also manufactures components for in-vehicle navigation and telematics systems, and timing modules used in the synchronization of wireless networks. The Company operates through four business segments: Engineering and Construction, Field Solutions, Mobile Solutions and Advanced Devices. In March 2009, the Company acquired QuickPen International.

Columbia Laboratories Inc. (Public, NASDAQ:CBRX) increased 3.65%, to close at $2.27 and its overall traded volume was 321,104.00 shares during the last session against its average volume of 1.13M. CBRX opened the day at $2.19, it made an intraday low of $2.19 and an intraday high of $2.28. The stock has a 52 week low of $0.88 and 52 week high of $2.43. CBRX’s market capitalization is 183.42M and it has 80.80M outstanding shares.

About Columbia Laboratories Inc. (Public, NASDAQ:CBRX)

Columbia Laboratories, Inc. (Columbia) focuses on developing products that utilize its bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. It focuses on funding new development projects through proof of concept, then partner for later-stage clinical development and commercialization. Its bioadhesive vaginal products provide solutions for infertility, pregnancy support, amenorrhea and other obstetric, gynecologic and medical conditions. CRINONE 8% (progesterone gel) is marketed by Watson Pharmaceuticals in the United States and by Merck Serono in foreign countries. STRIANT (testosterone buccal system) is marketed by Columbia (United States), The Urology Company (United Kingdom) and Sandoz (Italy).

iGATE Corporation (Public, NASDAQ:IGTE) decreased -2.67%, to close at $19.71 and its overall traded volume was 320,711.00 shares during the last session against its average volume of 906,324.00. IGTE opened the day at $20.17, it made an intraday low of $19.61 and an intraday high of $20.26. The stock has a 52 week low of $8.94 and 52 week high of $24.99. IGTE’s market capitalization is 1.10B and it has 55.86M outstanding shares.

About iGATE Corporation (Public, NASDAQ:IGTE)

iGATE Corporation (iGATE), through its operating subsidiaries, is a provider of information technology (IT) and IT- enabled operations offshore outsourcing services to large and medium-sized organizations. The Company targets large and medium-sized organizations across a diverse set of industries, including financial services, insurance, manufacturing, media and healthcare. The Company’s service offerings include IT and IT-enabled operations offshore outsourcing solutions and services to large and medium-sized organizations using an offshore/onsite model. These services include client/server design and development, conversion/migration services, offshore outsourcing, enterprise resource planning (ERP) package implementation and integration services, software development and applications maintenance outsourcing. It also offers integrated technology and operations (iTOPS) solutions that integrate IT outsourcing and IT-enabled operations offshore outsourcing solutions and services.

BreitBurn Energy Partners L.P. (Public, NASDAQ:BBEP) decreased -1.03%, to close at $20.14 and its overall traded volume was 319,186.00 shares during the last session against its average volume of 207,865.00. BBEP opened the day at $20.35, it made an intraday low of $20.10 and an intraday high of $20.64. The stock has a 52 week low of $10.55 and 52 week high of $20.89. BBEP’s market capitalization is 1.07B and it has 53.31M outstanding shares.

About BreitBurn Energy Partners L.P. (Public, NASDAQ:BBEP)

BreitBurn Energy Partners L.P. is an independent oil and gas partnership focused on the acquisition, exploitation and development of oil and gas properties in the United States. The Company’s assets consist of producing and non-producing crude oil and natural gas reserves located in the Antrim Shale in Michigan, the Los Angeles Basin in California, the Wind River and Big Horn Basins in central Wyoming, the Sunniland Trend in Florida and the New Albany Shale in Indiana and Kentucky. It conducts its operations through a wholly owned subsidiary, BreitBurn Operating L.P (BOLP) and BOLP’s general partner BreitBurn Operating GP, LLC (BOGP). Its wholly owned subsidiary, BreitBurn Management Company, LLC (BreitBurn Management), manages its assets and performs other administrative services.

CARDIOME PHARMA CORP (Public, NASDAQ:CRME) decreased -1.98%, to close at $6.42 and its overall traded volume was 318,350.00 shares during the last session against its average volume of 345,766.00. CRME opened the day at $6.55, it made an intraday low of $6.23 and an intraday high of $6.70. The stock has a 52 week low of $4.42 and 52 week high of $9.36. CRME’s market capitalization is 391.96M and it has 61.05M outstanding shares.

About CARDIOME PHARMA CORP (Public, NASDAQ:CRME)

Cardiome Pharma Corp. (Cardiome) is a life sciences company focused on developing drugs to treat or prevent cardiovascular diseases. The Company’s drug development efforts are focused on the treatment of atrial arrhythmias, a Phase I program for GED-aPC, an engineered analog of human activated protein C, and a pre-clinical program directed at improving cardiovascular function. As of December 31, 2009, Cardiome had five wholly owned subsidiaries: Rhythm-Search Developments Ltd., Artesian Therapeutics, Inc., Cardiome Development AG, Cardiome, Inc. and Cardiome UK Limited.